Tumor Mutational Burden and PD-L1 Expression in Hematologic Malignancies

被引：1
|
作者：
Thomas, Sean D.
Jeong, Ah-Reum
Sakowski, Patrick J.
Sokol, Ethan S.
Kurzrock, Razelle
Goodman, Aaron M.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
    Jeong, Ah-Reum
    Trando, Aaron H.
    Thomas, Sean D.
    Riviere, Paul
    Sakowski, Patrick J.
    Sokol, Ethan S.
    Goodman, Aaron M.
    Kurzrock, Razelle
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [2] Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies
    Thawani, Rajat
    Kartika, Thomas
    Elstrott, Benjamin
    Batiuk, Elizabeth
    Tao, Derrick
    Gowda, Sonia
    Chen, Lilian
    Lavasseur, Corinne
    Tun, Nattapron
    Taflin, Nicholas F.
    Shatzel, Joseph
    THROMBOSIS RESEARCH, 2022, 217 : 12 - 14
  • [3] PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    Yarchoan, Mark
    Albacker, Lee A.
    Hopkins, Alexander C.
    Montesion, Meagan
    Murugesan, Karthikeyan
    Vithayathil, Teena T.
    Zaidi, Neeha
    Azad, Nilofer S.
    Laheru, Daniel A.
    Frampton, Garrett M.
    Jaffee, Elizabeth M.
    JCI INSIGHT, 2019, 4 (06)
  • [4] Role of PD-L1 and Tumor Mutational Burden in NSCLC Immunotherapy
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S74 - S74
  • [5] PD-L1 and Tumor Mutational Burden Are Not Predictive of Thrombosis in a Cohort of 1,221 Patients with Solid Organ Malignancies
    Thawani, Rajat
    Kartika, Thomas
    Elstrott, Benjamin
    Batiuk, Elizabeth
    Chen, Lilian
    Tun, Nattapron
    Taflin, Nicholas
    Tao, Derrick Law
    West, Malinda T.
    Shatzel, Joseph J.
    BLOOD, 2021, 138
  • [6] Will Testing for Tumor Mutational Burden Bring the Same Challenges as Testing for PD-L1?
    Gupta V.
    Ramirez M.C.
    Schauser L.
    Genetic Engineering and Biotechnology News, 2019, 39 (06): : 56 - 57
  • [7] Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.
    Castellanos, Emily
    Snider, Jeremy
    Ali, Siraj Mahamed
    Backenroth, Daniel
    Albacker, Lee A.
    Murugesan, Karthikeyan
    Li, Gerald
    Frampton, Garrett M.
    Alexander, Brian Michael
    Carson, Kenneth Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL)
    Sumrall, Ashley
    Phuphanich, Surasak
    Spetzler, David
    Gatalica, Zoran
    Xiu, Joanne
    Provenzano, Aaron
    Brenner, Andrew J.
    Subramaniam, Deepa
    Pandey, Majari
    Heimberger, Amy
    Kesari, Santosh
    Korn, W. Michael
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2018, 20 : 240 - 241
  • [9] PD-L1 expression, tumor mutational burden, and microsatellite instability status in 746 pancreas ductal adenocarcinomas
    Hemmerich, Amanda
    Edgerly, Claire I.
    Duncan, Daniel
    Huang, Richard
    Danziger, Natalie
    Frampton, Garrett M.
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Killian, Jonathan Keith
    Lin, Douglas I.
    Williams, Erik
    Ali, Siraj Mahamed
    Reddy, Prasanth
    Miller, Vincent A.
    Owens, Clarence
    Brown, Charlotte
    Alexander, Brian M.
    Ross, Jeffrey S.
    Severson, Eric Allan
    Ramkissoon, Shakti H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [10] Loss of heterozygosity associates with PD-L1 expression and tumor mutational burden in high-grade endometrial tumors
    Mazina, Varvara
    Rueda, Bo
    Eisenhauer, Eric
    Bregar, Amy
    Philp, Lauren
    Watkins, Jaclyn
    Johnstone, Sarah
    Growdon, Whitfield
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S15 - S15
12345